Navigation Links
National Institute on Drug Abuse Director Nora Volkow Speaks about the Dangers of Narcotics on Azteca America's Political Forum 'Issues: Caras y Voces'
Date:12/11/2007

LOS ANGELES, Dec. 11 /PRNewswire/ -- Azteca America, the fastest-growing Hispanic television network in the United States, is proud to have hosted National Institute on Drug Abuse (NIDA) Director Nora Volkow on this Monday's broadcast of "Issues: Caras y Voces", a political forum hosted by veteran Latino journalist Armando Guzman.

Dr. Volkow, who has been the NIDA director since 2003, is a pioneer in demonstrating that drug addiction is a disease of the human brain. As a research psychiatrist and scientist, she has used brain imaging to investigate the toxic effects of drugs and their addictive properties.

During the segment, Dr. Volkow presented a computer enhanced video showing the harmful effects of cocaine on the brain due to the rapid dialation and constriction of blood vessels.

Dr. Volkow was born in Mexico, and earned her medical degree from the National Autonomous University of Mexico (UNAM) in Mexico City, where she received the Premio Robins award for best medical student of her class. Her psychiatric residency was at New York University, where she earned the Laughlin Fellowship Award as one of the 10 Outstanding Psychiatric Residents in the USA. She was recently named one of 20 people to watch by Newsweek magazine in its "Who's Next in 2007" special report.

"Issues: Caras y Voces" features top leaders that impact the Hispanic community through one-on-one interviews conducted by Armando Guzman. Covering the White House and the Capitol for almost two decades, Mr. Guzman is one of the most respected correspondents in Washington. The interview forum airs every Monday evening during Noticiero Azteca America, the network news broadcast of Azteca America.

Past guests of "Issues: Caras y Voces" include: New Mexico Governor Bill Richardson, California Governor Arnold Schwarzenegger, Senator Mel Martinez (R-FL), Congressman Xavier Becerra (D-CA), Senator Harry Reid (D-NV), former Massachusetts Governor Mitt Romney, Arizona
'/>"/>

SOURCE Azteca America; Grupo Salinas
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. International study strengthens case for daily calcium pill
2. Yakima Health Care Leader Tapped for Leadership Post at National Association
3. Virginia Tech Report Has National Importance
4. Donate Life America Dispels Myths About Organ & Tissue Donation Among Hispanics During National Hispanic Heritage Month
5. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. National Association of Subrogation Professionals (NASP), the Largest Insurance Subrogation Association in the World - Announced Today that Leslie Wiernik has Joined the Organization as Director of Education
8. 4-Star Gen. Barry McCaffrey, Former U.S. Drug Czar, to Address National Drug Crisis, Keynote Grand Opening of New Allenwood, PA National Model Detox Center
9. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
10. LCA Hails International Investigators Studying Lung Cancer
11. National Patient Safety Foundation Partners with Vocera Communications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2008)... The Accreditation Council ...ed the Education Division of the College of Americ...with Commendation as a provider of continuing medi... Northfield, IL (PRWEB) August 28, 2008 -- T...ucation (ACCME) has awarded the Education Division...
(Date:8/28/2008)... Popular Chef and March of Dimes Volunteer to tak...AINS, N.Y., Aug. 28 /PRNewswire-USNewswire/ -- Fro...n "Rock" Harper will be making the,rounds at ten M...public,nationwide this fall., Chef Rock is the Ma...erson. In this role, Chef Rock, winner of Fox Tele...
(Date:8/27/2008)... Thousands of medical students will gain access t...ng through REACHMD XM 157, the first satellite, ra...edical professionals., CHICAGO, Aug. 27 /PRNewswi...gic programming partnership with the American Medi...t and largest, independent,association for physici...
(Date:8/27/2008)...nding could lead to new drugs in fight against obe...(HealthDay News) -- A chemical produced in the bra...likelihood of becoming obese, according to a new s... group of 33 people who had WAGR syndrome, a genet...llion people. WAGR is an acronym for the symptoms ...
Breaking Medicine News(10 mins):Health News:College of American Pathologists' Education Division Receives Top Honor 2Health News:College of American Pathologists' Education Division Receives Top Honor 3Health News:Chef Rock to Rock Signature Chefs Auctions(R) Nationwide 2Health News:ReachMD, LLC Announces New Strategic Partnership With The American Medical Student Association 2Health News:ReachMD, LLC Announces New Strategic Partnership With The American Medical Student Association 3Health News:Low Levels of Brain Chemical May Control Appetite 2
...ulation shows that bone health is set to become a ...ods market. The lifetime risk for a woman to have ...in men the risk is about 13 per cent. Yet the main...m supplements are entering a mature category, and ...
...sity) is most common in older adults, particularly...es that will become a bigger and more costly probl...vitamin D has been shown to reduce the risk of fra... regarding how much of Vitamin D is needed has to ...
... of Human Organ Act was passed in India, we have n...been due to various reasons. //First and foremost ...ly consider this as an alternative to living organ...tiative from the Government after the act was pass...
...raise the level of inflammatory makers that influe...ublished by Archives of Neurology. Conditions of i...ated with elevated levels //of inflammatory marker...disease (AD). Inflammation has been proposed as a ...
Other Medicine News:Health News:The Potential Of Cadaver Transplantation Programme In India 2Health News:The Potential Of Cadaver Transplantation Programme In India 3
(Date:8/25/2008)...TEO, Calif., Aug. 25 /- Anthera Pharm...l company developing,anti-inflammatory drugs, toda...ecurrent Acute coronary events with Near-term Card...l designed to examine the impact of,varespladib wh...Acute,Coronary Syndrome (ACS) event., The FRANCIS...
(Date:8/22/2008)...Women Enrolled in Trial Sponsored by Medical Resea...e-FirstCall/ -- Indevus,Pharmaceuticals, Inc. (Nas...ollment in Protocol MDP 301, a Phase III clinical ... microbicide for the prevention of HIV and other,s...ored by the United,Kingdom,s Medical Research Coun...
(Date:8/22/2008)...LLE, Md., Aug. 22 /- Human ...nced that it has completed the,enrollment and init...al of,HGS-ETR1 (mapatumumab) in combination with t...as first-line therapy in advanced non-small cell,l...om/cgi-bin/prnh/20080416/HGSLOGO ), "There is an...
(Date:8/21/2008)...TAN, Kan., Aug. 21 /PRNewswire-USNewswire/ -- A re...oli O157:H7 expert T.G. Nagaraja has,been tapped b... the,connection between feeding distillers, grains...ies to reduce the presence of the naturally occurr...ved a $939,220 National Research Initiative in Foo...
Breaking Medicine Technology:Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial 2Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial 3Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 2Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 3Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 4Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 5Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer 2Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer 3Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer 4Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer 5K-State Researchers Awarded Nearly $1 Million to Test Remedies, Investigate Link Between E. Coli and Distillers' Grains 2Blood test takes step toward predicting Alzheimers risk Stanford researchers find 3623 1Blood test takes step toward predicting Alzheimers risk Stanford researchers find 3623 2Blood test takes step toward predicting Alzheimers risk Stanford researchers find 3623 3Blood test takes step toward predicting Alzheimers risk Stanford researchers find 3623 4Study reveals a key to blood vessel growth and possible drug target 794 1Study reveals a key to blood vessel growth and possible drug target 794 2Study reveals a key to blood vessel growth and possible drug target 794 3U S Unveils Database of Genetic Clinical Research 3620 1U S Unveils Database of Genetic Clinical Research 3620 2Governor Rendells Tour to Insure Urges Passage of Plan to Give Access to Affordable Health Insurance 3617 1Governor Rendells Tour to Insure Urges Passage of Plan to Give Access to Affordable Health Insurance 3617 2Governor Rendells Tour to Insure Urges Passage of Plan to Give Access to Affordable Health Insurance 3617 3
...s should find these data reassuring", PHILADELPHIA...thKline said today that findings from an interim a...diac Outcomes and,Regulation of glycemia in Diabet...cally to determine cardiovascular outcomes in more...rther evidence to,the overall cardiovascular safet...
...E)--Jun 5, 2007 - ERBITUX (cetuximab), the,first a...dermal,growth factor receptor (EGFR) developed and...as the focus of nine oral and 46,poster presentati...of the American Society of Clinical Oncology (ASCO...ed the extensive,clinical development of ERBITUX r...
Other Medicine Technology:Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 2Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 3Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 4Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 5Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 2Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 3Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 4Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 5Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 6Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 7Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 8Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 9Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 10
For proper plug sizing.
Skin Tone External Eyelid Weights
To prevent retraction of the conjunctival cul-de-sacs without touching the cornea.
For Frontalis Suspension in patients with significant ptosis and poor levator function.
Medicine Products: